Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
Status:
Completed
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
This study in healthy men and women looks at the injection site experience of semaglutide and
dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of
semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will
be given at least 30 minutes apart, one in each side of the stomach. Participants will be in
the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5
weeks after the injections were given.